vs
HARTE HANKS INC（HHS）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
HARTE HANKS INC的季度营收约是REGENXBIO Inc.的1.3倍（$39.9M vs $30.3M），HARTE HANKS INC净利率更高（5.5% vs -221.3%，领先226.9%），REGENXBIO Inc.同比增速更快（43.0% vs -15.4%），HARTE HANKS INC自由现金流更多（$-686.0K vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -6.4%）
哈特·汉克斯是一家总部位于美国马萨诸塞州波士顿的全球营销服务企业，主营业务涵盖数据分析、营销战略规划、营销技术支持、创意服务、数字营销、客户服务、直邮服务以及物流履约等多个领域，为全球客户提供全方位的营销解决方案。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
HHS vs RGNX — 直观对比
营收规模更大
HHS
是对方的1.3倍
$30.3M
营收增速更快
RGNX
高出58.4%
-15.4%
净利率更高
HHS
高出226.9%
-221.3%
自由现金流更多
HHS
多$52.1M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-6.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $39.9M | $30.3M |
| 净利润 | $2.2M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -0.3% | -190.0% |
| 净利率 | 5.5% | -221.3% |
| 营收同比 | -15.4% | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $0.30 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HHSRGNX
| Q4 25 | $39.9M | $30.3M | ||
| Q3 25 | $39.5M | $29.7M | ||
| Q2 25 | $38.6M | $21.4M | ||
| Q1 25 | $41.6M | $89.0M | ||
| Q4 24 | $47.1M | $21.2M | ||
| Q3 24 | $47.6M | $24.2M | ||
| Q2 24 | $45.0M | $22.3M | ||
| Q1 24 | $45.4M | $15.6M |
净利润HHSRGNX
| Q4 25 | $2.2M | $-67.1M | ||
| Q3 25 | $-2.3M | $-61.9M | ||
| Q2 25 | $-335.0K | $-70.9M | ||
| Q1 25 | $-392.0K | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $142.0K | $-59.6M | ||
| Q2 24 | $-27.8M | $-53.0M | ||
| Q1 24 | $-171.0K | $-63.3M |
毛利率HHSRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率HHSRGNX
| Q4 25 | -0.3% | -190.0% | ||
| Q3 25 | 1.3% | -176.3% | ||
| Q2 25 | 0.1% | -296.3% | ||
| Q1 25 | -0.1% | 13.6% | ||
| Q4 24 | -3.3% | -242.1% | ||
| Q3 24 | 4.0% | -256.6% | ||
| Q2 24 | 3.0% | -251.3% | ||
| Q1 24 | 0.8% | -408.8% |
净利率HHSRGNX
| Q4 25 | 5.5% | -221.3% | ||
| Q3 25 | -5.8% | -208.3% | ||
| Q2 25 | -0.9% | -331.8% | ||
| Q1 25 | -0.9% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | 0.3% | -246.3% | ||
| Q2 24 | -61.8% | -237.7% | ||
| Q1 24 | -0.4% | -405.4% |
每股收益（稀释后）HHSRGNX
| Q4 25 | $0.30 | $-1.30 | ||
| Q3 25 | $-0.31 | $-1.20 | ||
| Q2 25 | $-0.05 | $-1.38 | ||
| Q1 25 | $-0.05 | $0.12 | ||
| Q4 24 | $-0.31 | $-0.99 | ||
| Q3 24 | $0.02 | $-1.17 | ||
| Q2 24 | $-3.84 | $-1.05 | ||
| Q1 24 | $-0.02 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.6M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $20.5M | $102.7M |
| 总资产 | $91.8M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HHSRGNX
| Q4 25 | $5.6M | $230.1M | ||
| Q3 25 | $6.5M | $274.2M | ||
| Q2 25 | $4.8M | $323.3M | ||
| Q1 25 | $9.0M | $267.9M | ||
| Q4 24 | $9.8M | $234.7M | ||
| Q3 24 | $5.9M | $255.5M | ||
| Q2 24 | $11.0M | $290.4M | ||
| Q1 24 | $11.5M | $338.7M |
股东权益HHSRGNX
| Q4 25 | $20.5M | $102.7M | ||
| Q3 25 | $19.9M | $161.5M | ||
| Q2 25 | $22.2M | $213.7M | ||
| Q1 25 | $21.4M | $274.2M | ||
| Q4 24 | $21.7M | $259.7M | ||
| Q3 24 | $21.0M | $301.4M | ||
| Q2 24 | $20.6M | $348.3M | ||
| Q1 24 | $20.0M | $390.7M |
总资产HHSRGNX
| Q4 25 | $91.8M | $453.0M | ||
| Q3 25 | $92.7M | $525.2M | ||
| Q2 25 | $95.0M | $581.0M | ||
| Q1 25 | $100.6M | $490.9M | ||
| Q4 24 | $101.8M | $466.0M | ||
| Q3 24 | $108.1M | $519.1M | ||
| Q2 24 | $109.7M | $569.4M | ||
| Q1 24 | $113.4M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $737.0K | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-686.0K | $-52.8M |
| 自由现金流率自由现金流/营收 | -1.7% | -174.0% |
| 资本支出强度资本支出/营收 | 3.6% | 1.7% |
| 现金转化率经营现金流/净利润 | 0.33× | — |
| 过去12个月自由现金流最近4个季度 | $-4.5M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流HHSRGNX
| Q4 25 | $737.0K | $-52.3M | ||
| Q3 25 | $3.2M | $-56.0M | ||
| Q2 25 | $-4.8M | $-49.3M | ||
| Q1 25 | $-818.0K | $33.6M | ||
| Q4 24 | $4.0M | $-31.6M | ||
| Q3 24 | $-2.9M | $-40.5M | ||
| Q2 24 | $1.6M | $-45.5M | ||
| Q1 24 | $-5.7M | $-55.5M |
自由现金流HHSRGNX
| Q4 25 | $-686.0K | $-52.8M | ||
| Q3 25 | $2.2M | $-56.5M | ||
| Q2 25 | $-5.1M | $-49.7M | ||
| Q1 25 | $-923.0K | $32.6M | ||
| Q4 24 | $3.4M | $-32.7M | ||
| Q3 24 | $-4.9M | $-40.9M | ||
| Q2 24 | $926.0K | $-46.0M | ||
| Q1 24 | $-6.2M | $-56.0M |
自由现金流率HHSRGNX
| Q4 25 | -1.7% | -174.0% | ||
| Q3 25 | 5.5% | -189.9% | ||
| Q2 25 | -13.1% | -232.8% | ||
| Q1 25 | -2.2% | 36.6% | ||
| Q4 24 | 7.3% | -154.2% | ||
| Q3 24 | -10.2% | -168.9% | ||
| Q2 24 | 2.1% | -206.2% | ||
| Q1 24 | -13.7% | -358.5% |
资本支出强度HHSRGNX
| Q4 25 | 3.6% | 1.7% | ||
| Q3 25 | 2.5% | 1.7% | ||
| Q2 25 | 0.6% | 1.8% | ||
| Q1 25 | 0.3% | 1.2% | ||
| Q4 24 | 1.3% | 5.1% | ||
| Q3 24 | 4.0% | 1.3% | ||
| Q2 24 | 1.5% | 2.1% | ||
| Q1 24 | 1.2% | 3.6% |
现金转化率HHSRGNX
| Q4 25 | 0.33× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | -20.76× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HHS
| Fulfillment And Logistics Services | $17.3M | 43% |
| Customer Care | $13.7M | 34% |
| Other | $8.9M | 22% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
